Yonsei Med J.  2024 Apr;65(4):241-245. 10.3349/ymj.2023.0366.

The First Case of a Korean Patient with a MutationConfirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

• Lee SJ
• Baek JY
• Lee JY
• Kang JM
• Ahn JG

• KMID: 2554225
• DOI: http://doi.org/10.3349/ymj.2023.0366

Abstract

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an interleukin-6 inhibitor); tocilizumab administration every other week has completely alleviated the patient’s symptoms. Our report further expands the clinical spectrum of patients with TRAPS and reaffirms the use of tocilizumab as a viable alternative treatment option for those patients who are unsatisfactorily responsive to other commonly used biologics, such as canakinumab, anakinra, infliximab, and etanercept. Furthermore, our report may aid in increasing awareness about the existence of mutation-confirmed TRAPS in South Korea in addition to emphasizing the importance of actively pursuing genetic testing to correctly diagnose rare AID.

Keyword

TRAPS; TNFRSF1A; tocilizumab; tumor necrosis factor receptor-associated periodic syndrome; autoinflammatory disease